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The  Developing  Countries  Vaccine  Manufacturers  Network  (DCVMN)  assembled  high-proﬁle  leaders
from  global  health  organisations  and vaccine  manufactures  for its 16th  Annual  General  Meeting  to work
towards  a common  goal:  providing  quality  vaccines  for all people.
Vaccines contribute  to a healthy  community  and  robust  health  system;  the  Ebola  outbreak  has  raised
awareness  of the  threat  and  damage  one  single  infectious  disease  can  make,  and  it is clear  that  the  world
was  not  prepared.  However,  more  research  to better understand  emerging  infectious  agents  might  lead
to suitable  vaccines  which  help  prevent  future  outbreaks.
DCVMN  members  presented  their  progress  in  developing  novel  vaccines  against  Dengue,  HPV,  Chikun-
gunya,  Cholera,  cell-based  inﬂuenza  and other  vaccines,  demonstrating  the commitment  towards
eliminating  and  eradicating  preventable  diseases  worldwide  through  global  collaboration  and  technol-
ogy  transfer.  The  successful  introduction  of  novel  Sabin-IPV  and  Oral  Cholera  vaccine  in China  and  Korea
respectively  in 2015  was  highlighted.
In order  to achieve  global  immunisation,  local  authorities  and  community  leaders  play  an important
role  in the decision-making  in  vaccine  introduction  and  uptake,  based  on the  ability  of vaccines  to  protect
vaccinated  people  and protect  non-vaccinated  in  the  community  through  herd  immunity.  Reducing  the
risk of  vaccine  shortages  can  also  be  achieved  by increasing  regulatory  convergence  at  regional  and  inter-
national levels.  Combatting  preventable  diseases  remains  challenging,  and  collective  efforts  for  improving
multi-centre  clinical  trials,  creating  regional  vaccine  security  strategies,  fostering  developing  vaccine
markets  and  procurement,  and  building  trust  in  vaccines  were  discussed.
© 2016  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. Introduction
The Developing Countries Vaccine Manufacturers’ Network
DCVMN) convened its 16th international meeting, co-organised
y Queen Saovabha Memorial Institute (QSMI) and BioNet Asia,
nder the auspices of the Thai Red Cross Society. Nearly 300
rofessionals working in research, development, manufactur-
ng and supply of vaccines, from 30 countries, gathered in
angkok. DCVMN is the largest alliance of corporate manufactur-
rs, supplying over 300 vaccine types in various presentations to
mmunisation programmes, and contributing signiﬁcantly to global
ublic health efforts to eradicate polio, eliminate and control the
pread of known and emerging infectious diseases around the
orld.
Local health authorities and global health organisations rep-
esented at this meeting included United Nations International
 This report summarises the views of an international group of experts as pre-
ented at a scientiﬁc conference in a given time and context, and does not necessarily
epresent the decisions or the stated policy of any institution or corporation.
ttp://dx.doi.org/10.1016/j.vaccine.2016.02.067
264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
Children’s Fund (UNICEF), World Health Organization (WHO), Pan-
American Health Organization (PAHO), Gavi: The Vaccine Alliance,
Centres for Disease Control and Prevention (CDC), International
Vaccine Institute (IVI), Centre for Vaccine Ethics and Policy, PATH,
Clinton Health Access Initiative (CHAI), Bill & Melinda Gates Foun-
dation, European Vaccine Initiative, International Association of
Immunization Managers (IAIM), Sabin Vaccine Institute, Médecins
Sans Frontières (MSF), Hilleman Laboratories, Asian Paciﬁc Alliance
for Control of Inﬂuenza (APACI), National Institute for Biolog-
ical Standards and Control (NIBSC), Institute for Translational
Vaccinology (Intravacc) and other associations and non-proﬁt orga-
nisations. Representatives from about 40 vaccine manufacturers
from developing countries, and 26 life sciences corporations also
attended.
Prof. V. Sitprija, Director of Queen Saovabha Memorial Institute
and Mr.  V. Vonghangool, President of BioNet-Asia introduced Mr.
P. Wannamethee, Secretary General of the Thai Red Cross Soci-
ety, who  inaugurated the meeting by acknowledging the power
of preventive medicine to reduce, or even eliminate, disease-
related mortality and morbidity. The meeting was opened by M.
Suhardono, DCVMN President, who  re-stated the commitment of
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
ccine 34 (2016) 3562–3567 3563
t
c
D
t
2
o
i
r
e
e
u
a
i
g
p
r
3
M
[
a
f
n
s
i
o
f
p
v
a
d
d
m
i
I
m
i
i
(
I
c
v
d
(
(
R
r
l
t
a
a
W
a
s
h
l
DCVMs’ diversity
(Not exhaust ive illustra tion /examp le)
Parastata l
Global Actors
Local
Providers
Emerging
MNCs
New
Entrants
State-owned Privately Held
Ni
ch
e
La
rg
es
t
Market Driver
Pr
od
uc
t P
or
tfo
lio
/
Pr
od
uc
tio
n 
Sc
ale
Fig. 1. An illustration of Developing Countries’ Vaccine Manufacturers (DCVMs)
diversity segmented by (a) the breadth of the portfolio and scale of production and
(b)  whether the member is state or privately owned (and thus responding primarily
to  government or market forces). A sample of 18 DCVMs were mapped to these two
indicators resulting in 4 groupings or quadrants. The left quadrants include state-
owned manufacturers and the right quadrants include private sector manufacturers;
the  upper quadrants include large scale manufacturers of several vaccines for global
supply and the lower quadrants include small manufacturers of few vaccines for
niche or local supply. For example, a state-owned manufacturer with a large portfo-
lio and scale of production is noted with a black dot. (Production portfolio = number
of  products on the market; production scale = number of doses produced.) DCVM’sConference report / Va
he DCVMN to improve quality of life for every child, family and
ommunity globally. Prof. S. Khomvilai invited Dr. J.-M. Okwo-Bele,
irector at WHO, to speak on the achievements and challenges of
he Global Vaccine Action Plan (GVAP).
. Impact of vaccine procurement and supply in prevention
f diseases globally
J.-M. Okwo-Bele highlighted the achievements of global immun-
sation: polio eradication is close, with only two countries currently
eporting wild poliovirus; measles vaccination has reduced the dis-
ase by over 79% from 2000 to 2014 [1]; regional meningitis A
pidemics have been eliminated in Africa, with half of the pop-
lation vaccinated [2]; in all, around 6 million deaths have been
verted by vaccination [3]. Still, challenges remain. Limitations
n vaccine affordability and supply, failures in healthcare inte-
ration, disruption of immunisation by geopolitical conﬂict and
oor-quality health data have resulted in stagnant coverage and
epeated failure to reach immunisation goals. For instance, in 2014,
.2 million children missed their 3rd dose of DTP1 in the Eastern
editerranean region, mostly in security-compromised countries
4]. Solutions expected from manufacturers include measures to
ssure the controlled temperature chain (CTC) where cold-chain
acilities are lacking, implementation of improved delivery tech-
ologies for ease of use in the ﬁeld, and assistance in reducing risk of
hortages. The monitoring and accountability framework of GVAP
dentiﬁes and responds to immunisation challenges.
A. Batson, Chief Strategy Ofﬁcer at PATH, provided an overview
f the developing vaccine markets. Over the past decade, demand
or higher-value vaccines has grown. More antigens are incor-
orated into multi-valent combination vaccines (pentavalent2
accine replacing DTP, and MMR/MR3 replacing measles vaccine)
nd new, complex vaccines are being introduced. A robust vaccine
evelopment pipeline is emerging from both industrialised and
eveloping countries. From the latter, the Serum Institute of India’s
eningitis A vaccine reached 217 million people in 2015 [5], and
t is anticipated that Japanese encephalitis vaccine from Chengdu
nstitute, China, will reach 290 million people by 2017. DCVMN
embers play an essential role in global vaccine supply, contribut-
ng to improving health and driving new markets. They are diverse
n terms of ownership (state or private), scale, portfolio and market
local providers or emerging new multinational companies, Fig. 1).
t is important to understand their role and plan for anticipated
hanges in global versus national ﬁnancing and procurement of
accines.
S. Chunsuttiwat from the Ministry of Public Health, Thailand,
iscussed health security and Sustainable Development Goals
SDG). Thailand introduced universal health insurance coverage
UHC) in 2002, and reached 97.4% insurance coverage in 2009.
egionally, the Association of Southeast Asian Nations (ASEAN,
epresenting 10% of the world’s population [6]), has initiated col-
aboration for regional vaccine security and self-reliance, seeking
o understand vaccine needs from ASEAN countries’ perspectives,
nd to identify areas for cooperation.
The challenge of harmonising regulatory pathways to improve
ccess to vaccines in developing countries was discussed by M.
ard, from WHO. Increasing regulatory convergence at regionalnd international levels can be achieved by adopting common
tandards and practices for vaccine regulation, without requiring
armonisation of laws [7]. Such convergence and/or harmonisa-
1 DTP = diphtheria + tetanus + pertussis combination vaccines.
2 Pentavalent = DTP + Hepatitis B + Haemophilus inﬂuenzae type b or DTacellu-
arP + H. inﬂuenzae type b + inactivated poliovirus vaccines.
3 MMR/MR = measles (+mumps) + rubella vaccines.within each category frequently share common characteristics, for example, large
scale, private manufacturers typically have products that have been pre-qualiﬁed
by  WHO. DCVM’s within each category may also face similar challenges.
tion needs to be implemented consistently and intentionally to
succeed. WHO’s role in promoting access to quality medical prod-
ucts is to develop norms and standards and promote regulatory
convergence and harmonisation. Through WHO  initiatives, bene-
ﬁts and challenges can be identiﬁed, efﬁcient collaboration among
regulators fostered and in-country regulatory decisions supported.
Collaboration should replace duplication.
H. Deehan from UNICEF briefed the audience on prevention
and remediation strategies to manage vaccine supply constraints.
UNICEF’s procurement and supply of vaccines to countries needing
assistance with vaccination programmes has increased signiﬁ-
cantly over the years. Since 2013, more than 50% of doses procured
annually have been from suppliers in developing countries. Recent
supply constraints have included BCG4, yellow fever vaccine, and
IPV5 vaccine to support the polio endgame strategy. Early and trans-
parent communication with manufacturers and close monitoring
of stock levels within countries is required to allow prompt mit-
igation actions and ultimately reduce risk of interrupted supply.
Deehan invited DCVMN members to work with UNICEF to achieve
sustained global supply of affordable vaccines of assured quality.
M. Malhame, head of market shaping for Gavi, presented Gavi’s
recent accomplishments and activities. Pentavalent, pneumococ-
cal and rotavirus vaccines have been steadily introduced in a
growing number of countries, surpassing Gavi expectations. The
volume of vaccines from DCVMs6 continues to grow, although the
value of vaccines procured from DCVMs remains relatively low. To
secure global supply, Gavi has fostered procurement from mul-
tiple countries and manufacturers (Fig. 2A and B). In terms of
activities, Gavi introduced two major changes in their co-ﬁnancing
policy in 2015: (i) linking co-ﬁnancing to prices for all countries in
4 BCG = Bacillus Calmette–Guérin.
5 IPV = inactivated poliovirus vaccine.
6 DCVM = developing-country vaccine manufacturer.
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Fig. 2. World map of WHO  pre-qualiﬁed vaccine manufacturers supplying vaccines
to  Gavi procurement schemes. (A) in 2001, only 5 manufacturers from 5 produc-
ing countries were supplying WHO  prequaliﬁed vaccines, only 2 of which were in
developing countries. (B) in 2014, 16 vaccine manufacturers from 11 countries were
producing WHO  prequaliﬁed vaccines, with 11 of the manufacturers in developing
countries. Note: * Includes 14 Gavi suppliers and 2 manufacturers of prequaliﬁed
Gavi vaccines. ** One US manufacturer also produces in the Netherlands. Note: Coun-
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nant HPV vaccine candidate based on Escherichia coli expression
systems, developed by another manufacturer in China, is also in
phase 3 clinical trials, as previously reported [15].ry of production represents country of national regulatory agency responsible for
accine lot release. Source: UNICEF Supply Division and WHO  list of pre-qualiﬁed
accines 2014.
ransition phases and (ii) developing payment plans to help
ountries get out of default. Gavi’s strategic goals for 2016–2020
nclude a vaccine goal: to accelerate equitable uptake and coverage
f vaccines, a health system goal: to increase effectiveness and efﬁ-
iency of immunisation delivery as a part of strengthened health
ystems, a ﬁnancing goal: to improve sustainability of national
mmunisation programs, and a market-shaping goal: to shape mar-
ets for vaccines and other immunisation products [8]. With these
oals, Gavi hopes to immunise 300 million additional children
round the world by the end of 2020.
D. Rodriguez, from the PAHO Revolving Fund for vaccine pro-
urement took a moment to celebrate the Americas region’s
uccess, in 2015, as the ﬁrst region to eliminate rubella. This
as enabled by the commitment of member countries to regional
oals, the PAHO Revolving Fund and vaccine manufacturers. He
hen outlined challenges faced with vaccine shortages and strate-
ies to overcome these. Latin American populations are under the
hreat from yellow fever virus because vaccine demand exceeds
he number of doses available annually by 6–8 million [9]. To
void supply shortages, countries need concrete demand planning,
ecured budgets for vaccine purchases and careful stock manage-
ent. Prevention of shortages starts at country level, while PAHOcts regionally to facilitate timely and sufﬁcient supply, and vaccine
anufacturers worldwide are essential for assured global supply.
D. Steele, Bill & Melinda Gates Foundation, emphasised the
mportance to address global challenges for diarrheal disease vac-34 (2016) 3562–3567
cines. International partnerships with globally funded Product
Development Partnerships and DCVMs have already delivered two
vaccines for the prevention of leading causes of diarrheal mor-
tality, demonstrating the power of partnerships. First, a cholera
vaccine was  developed through partnership with Vabiotech,
Shantha Biotechnics, and the IVI [10]. The vaccine is WHO  pre-
qualiﬁed and is widely utilised in countries with endemic cholera.
Second, a rotavirus vaccine was developed in partnership with
Bharat Biotech, Indian Department of Biotechnology and PATH [11].
The vaccine is licensed in India for introduction in early 2016 and
a dossier is ready for WHO  prequaliﬁcation.
C. Egerton-Warburton elaborated on the goal of the Global
Health Investment Fund (GHIF): to invest in quality by suppor-
ting late-stage clinical trials and early-stage commercialisation of
vaccines, drugs, diagnostics and devices required for control of
infectious diseases in low-income countries, as to the World Bank
classiﬁcation7. An example is the investment in the Eubiologics
manufacturing facility for oral cholera vaccine, prequaliﬁed by the
WHO  in December 20158, testiﬁes the impact of ﬁnancial support
to start up manufacturers. Egerton-Warburton noted that new and
innovative ﬁnancing mechanisms, which complement the newly-
proposed revolving fund at UNICEF, may  be required to support
immunisation in non-Gavi countries.
3. Novel vaccines and technologies
While a large portfolio of new vaccines is under development
by manufacturers in developing countries, the conference focused
on a few novel and relevant results, due to time limitations. A.
Precioso, Director of Clinical Trials and Pharmacovigilance at Butan-
tan, reviewed the clinical development of a live, attenuated dengue
vaccine. The tetravalent vaccine is expected to protect against all
4 dengue serotypes, inducing both humoral and cellular immune
responses, and requires only one or two  doses to provide life-long
immunity. Phase I clinical trials in the US by NIH showed that one
dose of vaccine was  safe and immunogenic in both ﬂavivirus-naïve
and seropositive adults. Butantan is currently ﬁnalizing a Phase II
clinical trial, and ethical and regulatory approval for a Phase III trial
in Brazil is underway [12].
H.T. Pham, CEO of BioNet-Asia, outlined the development
of a recombinant pertussis vaccine in response to the resur-
gence of pertussis around the world. BioNet has constructed new
proprietary Bordetella pertussis strains which produce non-toxic,
genetically-inactivated pertussis toxin (rPT) [13]. In a Phase I/II
clinical trial, the rPT-containing vaccines were safe and immuno-
genic in healthy adults, and elicited signiﬁcantly higher anti-PT
titres than the conventional DTaP vaccine. Another Phase I study
will soon evaluate rPT vaccine with an epi-cutaneous delivery
system [14].
L. Shi, CEO of Shanghai Zerun Biotech, summarised the progress
made in recombinant HPV9 vaccine development. He reviewed the
strong causal relationship between HPV infection and cervical can-
cer. Zerun’s bivalent HPV (16/18) recombinant vaccine candidate,
produced in the yeast, Pichia pastoris, is currently in a Phase III clin-
ical trial, and is expected to be on the Chinese market by 2019,
and to obtain WHO  PQ thereafter. In addition, a novel recombi-7 http://data.worldbank.org/about/country-and-lending-groups.
8 WHO  prequaliﬁcation of oral cholera vaccine. Available at: http://www.who.int/
immunization standards/vaccine quality/pq 298 euvichol 1dose eubiologics/en/.
9 HPV = human papillomavirus.
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ket. Kim turned attention to the recent Ebola outbreak in Africa,Conference report / Va
L. Castello-Branco, Scientiﬁc Director at Fundac¸ ão Ataulpho de
aiva (FAP), presented an overview of the BCG vaccine (Moreau
ub-strain). This vaccine was developed in Brazil in the 1930s and
sed as an oral vaccine in the National Program on Immunisation
ntil 1974 [16]. Genetic data shows that the sub-strain is similar
o the Japanese and Russian sub-strains [17]. Safety and efﬁcacy of
ntradermal BCG-Moreau vaccine has been demonstrated in large
linical trials. It is the only BCG administered to babies born to HIV
ositive mothers in Brazil10 and it is licensed for use for intrav-
sical therapy of bladder cancer [18]. FAP is now expanding the
anufacturing capacity to supply BCG globally.
G. Liao described development of the Sabin IPV at the Institute of
edical Biology, Chinese Academy of Medical Sciences (IMBCAMS).
o accelerate eradication of circulating polioviruses from live polio
accines, WHO  launched an initiative to develop IPV. IMBCAMS
tarted Sabin-IPV development 1983. A successful phase III clinical
rial was completed in March 2013, and the world’s ﬁrst Sabin-IPV
accine was launched on the Chinese Market in July 2015. IMB-
AMS is planning to increase production capacity from the current
0 million to 60 million doses per annum, to develop a combination
accine and to obtain WHO  PQ11 to enable global supply [19].
K. Ella, Bharat Biotech, presented their Chikungunya vaccine,
n inactivated, whole-virion CHIKV derived from an Indian isolate
20]. CHIKV was established to high titre in Vero cells. Pre-clinical
oxicity studies demonstrated safety with 100 times the dose pro-
osed for Phase I testing. Phase I dose ranges were based on
 comparative study of protective correlates in 85 convalescent
atients and data from immunogenicity testing in laboratory ani-
als. A Phase I study is proposed in India. Vaccine methodology is
rotected by patents in several countries.
M. Bottazzi, from Sabin Vaccine Institute, reviewed novel tech-
ologies for vaccines against neglected tropical diseases. Seventeen
ropical diseases, including leprosy, trematodiasis, leishmaniasis,
engue, Chagas disease, ﬁlariasis and helminth infections are highly
revalent among the poor, and are endemic in 149 countries, affect-
ng 1.4 billion people [21]. The Sabin Vaccine Institute focuses
n product development partnerships to develop effective, low-
ost vaccines. The human hookworm vaccine initiative illustrates
hese efforts against a leading cause of maternal and childhood
naemia, which afﬂicts 440 million people. Two candidate vaccines
ave been manufactured and are currently being tested in Brazil
nd Gabon. The Institute is seeking partnership with manufactur-
rs from developing countries to advance the product and clinical
evelopment of various candidate vaccines.
The Eubiologics oral cholera vaccine (OCV) was presented by
. Park. Eubiologics has a contract manufacturing agreement with
VI for production and supply of cholera vaccines. Since 2013,
nvestments from Green Cross Corporation, GHIF and others have
upported the project. The goal in 2014 was to maintain a 2 million-
ose global stockpile, and thereafter, to gradually increase this to
0 million doses annually, ﬁnanced through Gavi. The stockpile
s expected to aid global response to outbreaks, improve over-
ll availability and supply of OCV, attract new manufacturers and
ncentivize new developments. Clinical trials were completed in
ugust 2014 [22]. This vaccine was approved in 2015 in Korea. A
requaliﬁcation dossier has been approved by WHO  demonstrating
he impact of partnerships among manufacturers.
Delivery of OCV was discussed by J. Deen, from the Deliver-
ng Oral Vaccines Effectively (DOVE) project at the Johns Hopkins
loomberg School of Public Health. Globally, there are an estimated
.8 million cases of cholera and nearly 100 000 deaths annually. Oral
10 Available at: http://bvsms.saude.gov.br/bvs/publicacoes/manual
rocedimentos vacinacao.pdf.
11 PQ = WHO  prequaliﬁcation.34 (2016) 3562–3567 3565
cholera vaccines provide direct and indirect (herd12) protection. In
2012 a global stockpile of 2 million doses of oral cholera vaccines
was created by WHO  primarily for epidemic response [23]. Vac-
cine supply is insufﬁcient to meet epidemic and endemic needs. If
vaccine supply is increased, OCV use can be expanded to endemic
countries to protect populations at risk and stop cholera.
K. Hun presented the novel cell-based seasonal inﬂuenza vac-
cine from SK Chemicals, licensed in Korea in 2014.
4. Executive discussion panels
4.1. The power of multi-centre clinical trials
A discussion was  moderated by O. Leroy, Executive Director
of the European Vaccine Initiative, with panellists A. Precioso, W.
Huang, D. Curry and V. Verez, about collaboration in clinical trials,
using vaccines developed at DCVMs Innovax and Finlay Institute as
examples. Innovax has produced the world’s ﬁrst hepatitis E vac-
cine [24], and is now using the recombinant technology platform to
produce, potentially, the world’s 3rd commercialised HPV vaccine.
Finlay is developing a 7-valent pneumococcal vaccine. Verez noted
that, as 70% of the world’s infants are not yet vaccinated against
pneumococcal disease, it may  be useful to have an affordable 7-
valent vaccine that protects against regional disease strains, while
waiting for higher valency vaccines to become accessible to mid-
dle and low-income populations. Head-to-head studies may  help
understand the impact of multivalent vaccines compared to region-
ally relevant formulations. Leroy asked how a manufacturer such as
Innovax could accelerate WHO  PQ and how DCVMN members could
support their clinical development. Huang stated that the DCVMN is
able to break barriers between countries and facilitate collaboration
and knowledge sharing; it is a matter of calling for such an initia-
tive. Harmonisation of the quality of clinical trials and DCVMN’s
role in calling for convergence between regulators was  encour-
aged. A. Precioso commented that DCVMN has several initiatives,
including workshops on clinical trial management to harmonise
practices and support WHO  prequaliﬁcation of vaccines. DCVMN
needs time to develop such complex initiatives, and collabora-
tions between companies can contribute, by enabling joint-clinical
development and international multicentric clinical trials. D. Curry
(Centre for Vaccine Ethics and Policy), whose expertise lies in
ethical and legal requirements for and oversight of clinical trials,
suggested that one area of support to DCVMs might be development
of ethical frameworks to guide clinical trial design, conduct and
assessment.
4.2. Vaccine security
A discussion on vaccine security was moderated by J. Kim, Direc-
tor General of IVI, with H. Deehan of UNICEF, M.  Makhoana of
Biovac, N. Premsri and T. Mahmoud as contributors. UNICEF and
Gavi are steadily increasing vaccine funding and procurement for
developing countries in response to increasing demand. H. Deehan
noted that, while sourcing vaccine from multiple suppliers helps
prevent global vaccine shortages, it also creates ﬁerce competition,
and noted the difﬁculty of ﬁnding the balance in having an ideal
number of suppliers and fostering a sustainable, competitive mar-which was  brought under control without a vaccine [25]. He posed
a question on how manufacturers can prepare for re-emergence.
12 Herd immunity, also called herd effect, community immunity, population
immunity, or social immunity, is a form of indirect protection from infectious dis-
ease that occurs when a large percentage of a population has become immune to
an  infection, thereby providing a measure of protection for individuals who are not
immune.
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.  Makhoana agreed that future outbreaks may  come, and empha-
ised that the understanding of the infectious agent must precede
roduct development. Vaccines then need to be part of broader
trengthening of health systems. Ultimately, responses tackling
frican diseases may  need to come from within Africa. Kim queried
accine security in Asia in the context of the regional threats with
ird ﬂu, SARS13 and MERS14. N. Premsri related Thailand’s philos-
phy of self-reliance, with the ideal to have capacity to produce
ssential vaccines and an adequate stockpile from multiple regional
anufacturers in order to respond to outbreaks or shortages. T.
ahmoud described vaccine-supply challenges in Saudi Arabia,
here the objective of high vaccination coverage is undermined
y vaccine shortages and lack of expertise in vaccine manufactur-
ng in the region. Technology transfer with the appropriate partners
nd a competent team of manufacturers will accelerate efforts to
ecure high vaccination coverage regionally.
.3. Developing markets
The discussion on developing markets was moderated by J. Chu,
enior Director of Vaccine Markets at the Clinton Health Access Ini-
iative (CHAI). He noted that vaccine markets are unique: it requires
 high investment for manufacturers, and the lengthy develop-
ent times, can often result unintentionally in supply monopoly.
hanges in regulatory standards can cause disruption and delays in
ot release and registration. Despite the challenges, DCVMN mem-
ers have been contributing signiﬁcantly to increasing access to
accines globally. In 2013, the human-vaccine market was  esti-
ated at US$25 billion and it is forecasted to reach US$38 billion
y 2020 [26]. To seize the opportunities and compete success-
ully in this rapidly growing global market, manufacturers need
o continuously innovate. M.  Malhame (Gavi) raised the balance
etween affordability and sustainability of vaccine supply, explain-
ng that Gavi evaluates any new vaccine that has passed phase
I clinical trials for inclusion in the vaccines’ portfolio ﬁnanced
y Gavi. This evaluation is data-driven, and includes parameters
uch as disease burden, feasibility and cost-effectiveness of disease
revention. However, she noted that coordination and alignment
etween global stakeholders need to improve and ensure develop-
ent of the most needed vaccines. She also commented that the
igh costs of vaccine development, relative to those of drugs or
iagnostics, could be overcome in part by technologies to improve
anufacturing processes. K. Ella (Bharat Biotech) shared insights
n building successful international partnerships and balancing
rivate and public contributions. Privatisation of manufacturing
as resulted in stable vaccine supply in many countries, and pri-
ate enterprise can enhance supply of public-sector. L. Shi (Zerun
nstitute, Walvax) discussed corporate motivation to enter interna-
ional markets while also serving the needs of domestic markets.
alvax is prioritizing product-portfolio investments to allow sup-
ly of vaccines internationally. Large manufacturing capacity is
equired to satisfy both domestic and international markets and
any Chinese companies have this capacity, thus the world is likely
o see more vaccines from Chinese manufacturers in future. F. Lobos
escribed Sinergium’s journey into the vaccine market in South
merica. Sinergium was a spin-off from a veterinarian vaccine man-
facturer in 2009. It established technology transfer agreements
ith large multinationals, primarily to satisfy the national needs
or inﬂuenza, pneumococcal and HPV vaccines. Importantly, part-
erships with government accelerated their progress: technical
13 Severe Acute Respiratory Syndrome (SARS) cf. http://www.who.int/csr/sars/
n/.
14 Middle East respiratory syndrome cf. http://www.who.int/mediacentre/
actsheets/mers-cov/en/.34 (2016) 3562–3567
support was received from the local regulatory agency in build-
ing a world-class facility complying with international standards;
also, a multi-year governmental supply contract secured stability
for the company. Both local and international partners were critical
for rapid success. Now, with modern facilities and equipment, the
company aims to expand partnerships with DCVMs.
4.4. Trust in vaccines
S. Inglis, director of NIBSC, moderated the panel that included
S. Jadhav (Serum Institute of India), A. Batson (PATH), P. Carrasco
(IAIM), and K. Sampson (APACI) on trust in vaccines. S. Jadhav
described the experiences of the Serum Institute of India, one
of the largest and most successful manufacturers from emerg-
ing countries, with 23 WHO-prequaliﬁed vaccines. Still reluctance
to purchase products from developing countries on the basis of
perceived higher reactogenicity or preference for known brands
is a barrier to acceptance of new products. Measles vaccine was
prequaliﬁed by WHO  in 1993, however UNICEF did not immedi-
ately take it up. Serum Institute supplied more than 90% of the
measles-containing vaccines used to achieve measles and rubella
eradication in Latin America. For the introduction of meningitis A
vaccine in African countries, community leaders were informed
about beneﬁts, resulting in high acceptance and very successful
prevention of disease. The lesson is that industry needs to invest
considerable effort into informing stakeholders of their products
and intentions. A. Batson noted that vaccine hesitancy is often spe-
ciﬁc to a country or situation, rather than a global issue, and strongly
agreed that engaging the local community leaders can have signif-
icant impact on uptake. Interestingly, mobile phones have proven
useful to advocate for vaccines for teenagers, such as HPV vaccines.
K. Sampson discussed the conﬁdence in inﬂuenza vaccines, where
there is a risk that the strains that make up the vaccine may  not fully
match those causing disease, due to antigenic drift. He noted that
Asia has a large ethnically and socio-culturally heterogeneous pop-
ulation and a vaccine may  not suit all patients. Decision-making on
inﬂuenza vaccination is driven by whether it is likely to protect the
vaccinated individual, and also, whether is it likely to help protect
others through herd immunity. Ready availability of disease data
that can be communicated to medical professionals would assist
in highlighting value. P. Carrasco elaborated further on the role of
health workers delivering vaccines, noting that they build patient
trust by imparting their knowledge of the vaccines and vaccination,
but also inspire conﬁdence when they clearly trust the interven-
tion themselves. Educational programs, organised by professional
associations, need to provide health professionals with the right
information about why and how vaccines are used, in their own
language. New tools, such as smart phones, are within reach of most
health workers, even in low-income countries.
5. Conclusions
The DCVMN 2015 Annual General Meeting gave rich insights
into advances in vaccine technologies and development of new
vaccines, and provided valuable opportunity for vaccine manu-
facturers, regulatory authorities and international organisations
to have face-to-face interactions. To achieve global immunisation,
local authorities and community leaders play an important role
in the decision-making in vaccine introduction and uptake, based
on the ability of vaccines to protect vaccinated people and protect
non-vaccinated in the community through herd immunity. Reduc-
ing the risk of vaccine shortages can be achieved by increasing
regulatory convergence at regional and international levels. Com-
batting preventable diseases outbreaks remains challenging, and
collective efforts for improving multi-centre clinical trials including
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arious populations, creating regional relevant vaccine manufac-
uring and stockpiling security strategies, fostering stable vaccine
arkets and procurement, and building trust in vaccines are rec-
mmended approaches. The DCVMN members will continue to
ollaborate with one another, with partners and with regulators
owards the goal of improving global access to immunisation,
hrough sustainable supply of vaccines to match demand, as well
s greater capacity to rapidly respond to outbreaks. The aim is to
rovide high quality vaccines for all people.
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